Product Description
Apixaban is used help prevent strokes or blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes) that is not caused by heart valve disease. Apixaban is also used to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg) and pulmonary embolism (PE; a blood clot in the lung) in people who are having hip replacement or knee replacement surgery. Apixaban is also used to treat DVT and PE and may be continued to prevent DVT and PE from happening again after the initial treatment is completed. Apixaban is in a class of medications called factor Xa inhibitors. It works by blocking the action of a certain natural substance that helps blood clots to form. (Sourced from: https://medlineplus.gov/druginfo/meds/a613032.html)
Mechanisms of Action: VKOR Antagonist,FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Atrial Fibrillation | Embolism | Embolism and Thrombosis | Thrombosis | Stroke | Pulmonary Embolism
Known Adverse Events: Injuries/wounds Unspecified
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Canada, China, France, Germany, Greece, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atrial Fibrillation|Kidney Diseases|Kidney Failure, Chronic|Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential|Thrombosis
Phase 2: Healthy Volunteers|Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AVAJAK | P3 |
Active, not recruiting |
Thrombocythemia, Essential|Polycythemia Vera|Myelofibrosis |
2026-06-03 |
|
| TAH3311-CP-2301 | P2 |
Not yet recruiting |
Healthy Volunteers |
2025-01-01 |
|
| API-CAT | P3 |
Completed |
Thrombosis |
2024-09-06 |
|
| DOAC LVAD | P2 |
Completed |
Heart Failure |
2023-10-05 |